Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $8.50 Average PT from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average recommendation of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.67.

Several brokerages have commented on SGMO. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Piper Jaffray Companies set a $8.00 price target on Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Thursday. BidaskClub lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Wedbush restated a “neutral” rating and set a $4.00 price target (down from $6.00) on shares of Sangamo Therapeutics in a research note on Tuesday, May 16th. Finally, Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th.

Shares of Sangamo Therapeutics (NASDAQ SGMO) opened at 10.25 on Friday. The stock’s 50 day moving average is $9.08 and its 200 day moving average is $6.17. The company’s market cap is $855.66 million. Sangamo Therapeutics has a 52-week low of $2.65 and a 52-week high of $10.50.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $8.30 million during the quarter, compared to analyst estimates of $5.82 million. Sangamo Therapeutics had a negative return on equity of 42.68% and a negative net margin of 246.39%. The business’s quarterly revenue was up 124.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.38) earnings per share. Equities analysts forecast that Sangamo Therapeutics will post ($0.98) EPS for the current year.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the transaction, the vice president now owns 35,517 shares of the company’s stock, valued at approximately $355,170. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 8.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Blair William & Co. IL boosted its stake in shares of Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 500 shares during the last quarter. Aperio Group LLC bought a new stake in shares of Sangamo Therapeutics during the second quarter worth $108,000. Principal Financial Group Inc. boosted its stake in shares of Sangamo Therapeutics by 6.8% in the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 832 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Sangamo Therapeutics during the second quarter worth $124,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Sangamo Therapeutics during the second quarter worth $126,000. Institutional investors and hedge funds own 58.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/12/sangamo-therapeutics-inc-nasdaqsgmo-receives-8-50-consensus-pt-from-brokerages-updated-updated-updated.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

What are top analysts saying about Sangamo Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sangamo Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit